Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Journal of Clinical Oncology - United States
doi 10.1200/jco.2012.44.8027
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer

Cancer Biotherapy and Radiopharmaceuticals
Nuclear MedicineRadiologyPharmacologyCancer ResearchOncologyImagingMedicine
2010English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Cancer
Cancer ResearchOncology
2019English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Cancer
Cancer ResearchOncology
2019English

A Phase II, Randomized, Multicenter Study Evaluating the Combination of Lapatinib and Vinorelbine in Women With ErbB2 Overexpressing Metastatic Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2014English

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Pregnancies During and After Trastuzumab and/or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Analysis From the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) Trials

Cancer
Cancer ResearchOncology
2018English

Locoregional Therapy With Α-Emitting Trastuzumab Against Peritoneal Metastasis of Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer in Mice

Cancer Science
Cancer ResearchMedicineOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy